SCHEDULE 13D/A: EcoR1 Capital Significantly Reduces Stake in Prothena, Selling Over 6 Million Shares

Investment firm EcoR1 Capital and its affiliates have significantly reduced their beneficial ownership in Prothena Corp Public Ltd Co, selling over 6.2 million ordinary shares in early May 2025.

Summary

• EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. (the "reporting persons") have filed an Amendment No. 5 to their Schedule 13D regarding their beneficial ownership in Prothena Corp Public Ltd Co.
• As of May 6, 2025, EcoR1 Capital, LLC and Oleg Nodelman beneficially own 5,304,596 Ordinary Shares, representing 9.9% of the class.
• EcoR1 Capital Fund Qualified, L.P. beneficially owns 4,973,891 Ordinary Shares, representing 9.2% of the class.
• These percentages are calculated based on 53,826,982 Ordinary Shares outstanding as of February 20, 2025, as reported in the Issuer's Form 10-K.
• The reporting persons initially acquired the shares for investment purposes, believing them to be undervalued and an attractive opportunity.
• In the 60 days preceding the filing, specifically between May 2 and May 6, 2025, the Funds sold a total of 6,279,684 Ordinary Shares.
• Sales occurred on May 2, 2025 (3,317,938 shares at a dollar-weighted average price of $8.3621 per share), May 5, 2025 (977,693 shares at $8.1111 per share), and May 6, 2025 (1,984,053 shares at $7.6433 per share).
• The initial investment by EcoR1 Capital Fund Qualified, L.P. was $91,817,329.79, and by EcoR1 Capital Fund, L.P. was $2,414,147.63, with funds sourced from their working capital.

Sentiment

Score: 3

Explanation: The substantial sale of over 6.2 million shares by a major investment firm, coupled with a declining average sale price over the transaction period, indicates a negative sentiment or a strategic exit by the reporting persons regarding their investment in Prothena.

Positives

• The reporting persons initially acquired shares because they believed the Issuer's Ordinary Shares were undervalued and represented an attractive investment opportunity.

Negatives

• The reporting persons have significantly reduced their stake in Prothena, selling over 6.2 million shares in early May 2025.
• The average selling price decreased over the three reported sale dates, from $8.3621 on May 2, 2025, to $7.6433 on May 6, 2025.

Risks

• The document does not explicitly state risks for the issuer, but the significant reduction in a large shareholder's stake could be perceived as a negative signal and potentially lead to downward pressure on the stock price.

Future Outlook

The reporting persons will routinely monitor the Issuer's performance, including current and anticipated future trading prices, operations, assets, prospects, financial position, business development, management, competitive and strategic matters, and general economic, financial market, and industry conditions. They may purchase additional Ordinary Shares, sell existing holdings, or enter into hedging or other derivative transactions. While they have no present plan for specific corporate actions (such as mergers or changes in control), they may recommend such actions to the Issuer's management, board of directors, and stockholders.

Management Comments

• "The reporting persons acquired Ordinary Shares for investment purposes based on their belief that the Issuer's Ordinary Shares, when purchased, was undervalued and represented an attractive investment opportunity."
• "The reporting persons will routinely monitor the Issuer regarding a wide variety of factors that affect their investment considerations."
• "Depending on their evaluation of various factors, the reporting persons may take such actions regarding their holdings of the Issuer's securities as they deem appropriate in light of circumstances existing from time to time."
• "The reporting persons have no present plan or proposal that relates to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D. However, the reporting persons may recommend action to the Issuer's management, board of directors and stockholders."

Industry Context

This document details the investment activities of EcoR1 Capital, an investment firm, in Prothena Corp Public Ltd Co. It focuses on changes in beneficial ownership and investment intent rather than broader industry trends or the operational context of Prothena's specific sector.

Comparison to Industry Standards

• The document does not provide sufficient information regarding Prothena's operational or financial performance to allow for a comparison to global benchmarks, specific comparable companies, or industry standards.

Related Party Transactions

• EcoR1 Capital, LLC acts as the investment adviser to its clients, including EcoR1 Capital Fund Qualified, L.P., pursuant to investment management agreements or limited partnership agreements.
• EcoR1 Capital, LLC is the general partner of the Funds.
• Oleg Nodelman is the manager and control person of EcoR1 Capital, LLC.
• EcoR1 is entitled to allocations and fees based on assets under management and realized/unrealized gains from its clients.
• The reporting persons have an agreement to file jointly any required statements under Sections 13(d) and 16(a) of the Securities Exchange Act of 1934.

Stakeholder Impact

• Shareholders: The significant reduction in stake by a major institutional investor could lead to increased selling pressure on the stock and may be interpreted as a negative signal regarding the company's future prospects or valuation.

Next Steps

• The reporting persons may purchase additional Ordinary Shares or sell remaining holdings in the open market or privately.
• They may enter into or unwind hedging or other derivative transactions with respect to the Ordinary Shares.
• They may pledge their interests in the Ordinary Shares to obtain liquidity.
• They may communicate with other stockholders, industry participants, and interested parties about the Issuer.
• They may recommend actions to the Issuer's management, board of directors, and stockholders, potentially including mergers, consolidations, sales or acquisitions of assets, changes in control, issuances, purchases, dispositions or pledges of securities, or other changes in capitalization.

Key Dates

Recommendation

Keywords

Prothena Corp Public Ltd Co, EcoR1 Capital, Schedule 13D, Beneficial Ownership, Share Sales, Investment Fund, SEC Filing, Ordinary Shares, Institutional Investor